Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Other Non Operating Income (2016 - 2025)

Spero Therapeutics' Other Non Operating Income history spans 10 years, with the latest figure at $2000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 107.69% year-over-year to $2000.0; the TTM value through Dec 2025 reached $7000.0, down 88.33%, while the annual FY2025 figure was $7000.0, 88.33% down from the prior year.
  • Other Non Operating Income reached $2000.0 in Q3 2025 per SPRO's latest filing, down from $4000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $963000.0 in Q4 2022 to a low of -$118000.0 in Q1 2021.
  • Average Other Non Operating Income over 5 years is $36555.6, with a median of -$8000.0 recorded in 2022.
  • The largest YoY upside for Other Non Operating Income was 3200.0% in 2024 against a maximum downside of 600.0% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$78000.0 in 2021, then soared by 1334.62% to $963000.0 in 2022, then plummeted by 99.69% to $3000.0 in 2023, then surged by 3200.0% to $99000.0 in 2024, then tumbled by 97.98% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Other Non Operating Income are $2000.0 (Q3 2025), $4000.0 (Q2 2025), and $1000.0 (Q1 2025).